EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinicopathological Differences in HER2 Immunohistochemical Expression Between Low-Grade Endometrial Cancer with p53-Abnormal Expression and High-Grade Endometrial Cancer

Kazuhisa Hachisuga iD, Miya Nakashima, Yoshihiro Katayama, Yusuke Inomata iD, Hiroshi Tomonobe iD, Shoji Maenohara, Keisuke Kodama iD, Hiroshi Yagi, Ichiro Onoyama iD, Kazuo Asanoma iD, Yoshinao Oda, Hideaki Yahata

Cancers · 15.08.2026 · 18 (16) · 2638

DOI: 10.3390/cancers18162638 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 15.08.2026. Verfasst von Kazuhisa Hachisuga und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seiichi Imai Memorial Foundation Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Under the current molecular classification of endometrial cancer, the p53-abnormal group is defined as having the worst prognosis, but the clinicopathological position of low-grade endometrial cancer with p53-abnormal expression relative to high-grade endometrial cancer remains unclear. We previously showed that low-grade endometrial cancer with p53-abnormal expression more closely resembles low-grade endometrial cancer with p53 wild-type expression than high-grade endometrial cancer and that the ERBB2 gene, encoding Human Epidermal Growth Factor Receptor 2 (HER2) protein, is more highly expressed in high-grade endometrial cancer. This study compared HER2 immunohistochemical expression (IHC) among low-grade endometrial cancer with wild-type p53 expression (EClop53wt), low-grade endometrial cancer with p53-abnormal expression (EClop53ab), and high-grade endometrial cancer (EChi), in order to characterize EClop53ab.

Methods

We retrospectively analyzed 70 endometrial cancer cases treated at Kyushu University Hospital in 1992–2022. Tumors were classified as EClop53wt, EClop53ab, and EChi based on histopathology and p53 immunohistochemistry, with EChi corresponding to conventional uterine serous carcinoma. HER2 expression was evaluated immunohistochemically using a standardized scoring system (0, 1+, 2+, 3+), and its distribution was compared across the three groups, together with clinicopathological parameters and patient outcomes.

Results

EChi showed the highest frequency and intensity of HER2 expression, with a substantially larger proportion of HER2 IHC 3+ cases than EClop53wt and EClop53ab (p < 0.0001 and p = 0.0146, respectively). Meanwhile, there was no significant association between EClop53wt and EClop53ab (p = 0.3794). In addition, HER2 IHC 3+ had significant associations with older age (≥60 years) and substantial lymphovascular space invasion (p = 0.0003 and 0.0174, respectively).

Conclusions

EClop53ab exhibits HER2 profiles and clinical behavior more similar to EClop53wt, supporting the more nuanced application of molecular classification and HER2-targeted therapy in endometrial cancer.

Schlagwörter

Stichwörter der Autor:innen

HER2 expressionclinicopathological featureendometrial carcinomap53-abnormal expression

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
  • Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

ORCID-Profile: Kazuhisa Hachisuga, Yusuke Inomata, Hiroshi Tomonobe, Keisuke Kodama, Ichiro Onoyama, Kazuo Asanoma

Förderung

  • Seiichi Imai Memorial Foundation Research Grant

Zitieren

APA

Hachisuga, K., Nakashima, M., Katayama, Y., Inomata, Y., Tomonobe, H., Maenohara, S., Kodama, K., Yagi, H., Onoyama, I., Asanoma, K., Oda, Y., & Yahata, H. (2026). Clinicopathological Differences in HER2 Immunohistochemical Expression Between Low-Grade Endometrial Cancer with p53-Abnormal Expression and High-Grade Endometrial Cancer. Cancers, 18(16), 2638. https://doi.org/10.3390/cancers18162638

Vancouver

Hachisuga K, Nakashima M, Katayama Y, Inomata Y, Tomonobe H, Maenohara S, et al. Clinicopathological Differences in HER2 Immunohistochemical Expression Between Low-Grade Endometrial Cancer with p53-Abnormal Expression and High-Grade Endometrial Cancer. Cancers. 2026;18(16):2638. doi:10.3390/cancers18162638

BibTeX
@article{Hachisuga2026,
  author = {Hachisuga, Kazuhisa and Nakashima, Miya and Katayama, Yoshihiro and Inomata, Yusuke and Tomonobe, Hiroshi and Maenohara, Shoji and Kodama, Keisuke and Yagi, Hiroshi and Onoyama, Ichiro and Asanoma, Kazuo and Oda, Yoshinao and Yahata, Hideaki},
  title = {Clinicopathological Differences in HER2 Immunohistochemical Expression Between Low-Grade Endometrial Cancer with p53-Abnormal Expression and High-Grade Endometrial Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2638},
  doi = {10.3390/cancers18162638}
}
Kostenlos starten →